- AdventHealth
AdventHealth physician says it could lead to more treatment options for kidney patients and others

New research, conducted in part at AdventHealth, shows medicines like Ozempic can dramatically reduce the risk of serious illness in people with kidney disease.
“In the near future, this treatment could become one of the pillars of therapy for patients with Type 2 diabetes (T2D) and chronic kidney disease because of the powerful effects this study shows, not just on kidney progression, but on heart disease and mortality,” said Dr. Richard E. Pratley, senior investigator at the AdventHealth Translational Research Institute. “This treatment positively affects multiple organs to decrease risk and this study confirms it’s a whole body, holistic type of treatment. It’s not just a medication focused on lowering blood sugar; it has other major benefits.”
Pratley believes this research supports Ozempic as a life-saving option for a new set of patients. He is the senior author on a recently published study in the New England Journal of Medicine (NEJM) article which looks at the effects of Ozempic in persons with Type 2 diabetes patients with chronic kidney disease.
The trial, called FLOW, evaluated the efficacy and safety of semaglutide (Ozempic) given once weekly in people with T2D and chronic kidney disease from preventing:
- Kidney failure
- Substantial loss of kidney function
- Death from kidney or cardiovascular causes
The groundbreaking study results show promising outcomes and Pratley is confident it will quickly obtain FDA approval, making Ozempic a life-saving option for a new set of patients for whom additional treatment options are badly needed.
“This research shows us where Ozempic’s strengths lie,” Pratley said. “Ozempic has demonstrated efficacy with many of the important complications associated with type 2 diabetes, including heart and kidney disease.”
The study results of over 3,500 participants who were followed for an average of 3.4 years showed:
- 24% lower risk of kidney events worsening kidney function, transplant dialysis, kidney death and cardiovascular disease
- 18% lower risk of major cardiovascular events (heart attack, stroke, etc.)
- 20% lower risk of death
“By sharing these insights with other physicians and clinicians through the NEJM, we hope our findings will eventually become the standard of whole person care globally to improve patient outcomes.”
This is the first study of its kind to examine a GLP-1 receptor agonist (semaglutide) and its effects on kidney outcomes and with promising results, Pratley hopes to drive change in screening for kidney disease.
“There’s a big gap in the number of patients who have kidney disease and the number who are diagnosed,” said Pratley. “Screening needs to start happening with the primary care physician to identify kidney disease in its early stages because we now have treatments that can prevent disease progression.”
In addition to these new findings, there are also other potential benefits of Ozempic being explored, such as improving heart failure in patients and even secondary benefits like improving liver disease and sleep apnea.
Recent News
The AdventHealth Neuroscience Institute is the first in Florida and one of the first in the country to begin recruiting patients with primary progressive or non-active secondary progressive multiple...
Accurately determining food intake remains a challenge in nutrition research. A new study published in Nature Metabolism and co-authored by Dr. Corbin introduces a metagenomics-powered approach to...
Discover what’s being accomplished in Central Florida to bridge the health gap with Orange County Mayor Jerry Demings and AdventHealth’s Dr. Alric Simmonds.
Breakthrough device offers new hope for stroke survivors struggling with rehabilitation following ischemic stroke
Jennifer Seminerio, MD, recently became one of the first in Florida to use intestinal ultrasound (IUS) to help assess and manage treatment of patients with inflammatory bowel disease (IBD). A non...
The Convergent Hybrid Ablation procedure has been gaining acceptance as an effective treatment option for long-standing persistent atrial fibrillation (AFib) since the CONVERGE trial data published in...
Recently, AdventHealth for Children pediatric orthopedic surgeon Sean Keyes, DO, Katelyn Smith, PA-C, and their team performed their 100th bridge-enhanced anterior cruciate ligament (ACL) repair (BEAR...
Physician leaders from AdventHealth’s emergency department, infectious disease, inpatient, pediatrics and pharmacy teams all collaborated to develop a respiratory virus testing algorithm to assist...
Thoracic surgeon Colleen Gaughan, MD, and her team at AdventHealth Celebration, recently became one of the first in the country to incorporate targeted imaging agent Cytalux (pafolacianine) as part of...
On the newest Inspiring Wholeness podcast, Obie Diaz, local morning radio show host, shares how a routine physical eventually led to two open heart surgeries.
AdventHealth recently began piloting a new Genomics Risk Assessment for Cancer and Early Detection (GRACE) program that combines the use of digital mammography, artificial intelligence (AI) technology...
AdventHealth Clinical Research Unit (CRU) Executive Director and Medical Director of Genitourinary Oncology Guru Sonpavde, MD, co-authored an article on the AMBASSADOR Phase III clinical trial results...